Linked Life Data

21277964

Source:http://linkedlifedata.com/resource/pubmed/id/21277964

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2011-4-1
pubmed:abstractText
Targeted uptake of therapeutic nanoparticles in tumor cells-specific manner represents a potentially powerful technology in cancer therapy. In present study, we proposed a drug delivery system formulated with biocompatible and biodegradable cholesterol-block-poly (ethylene glycol) (Chol-PEG(2000)-COOH) polymer. And the surface of the polymer was chemically linked with truncated bFGF fragments (tbFGF). The tbFGF could recognize fibroblast growth factor receptors (FGFR) that are highly expressed by a variety of human cancer cells. The micelles had a size distribution of about 10-50 nm and significantly enhanced the cytotoxicity of paclitaxel to LL/2 cells as demonstrated by MTT test (IC??=0.21 ?g/mL for tbFGF conjugated Chol-PEG(2000)-COOH micelles (tbFGF-M-PTX) versus 26.43 ?g/mL for free paclitaxel, respectively). Flow cytometry revealed the cellular uptake of rhodamine B encapsulated in the tbFGF-conjugated micelles was increased by 6.6-fold for HepG2, 6.2-fold for A549, 2.9-fold for C26 and 2.7-fold for LL/2 tumor cells, respectively, compared with micelles without tbFGF. The fluorescence spectroscopy images further demonstrated that the tbFGF conjugated micelles could specifically bind to the tumor cells that over-expressed FGFRs and then release rhodamine B into the cytoplasm. Our results suggest the tbFGF conjugated Chol-PEG(2000)-COOH micelles have great potential application for tumor targeting therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1873-3476
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
408
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
173-82
pubmed:meshHeading
pubmed-meshheading:21277964-Animals, pubmed-meshheading:21277964-Antineoplastic Agents, pubmed-meshheading:21277964-Cell Line, Tumor, pubmed-meshheading:21277964-Cell Survival, pubmed-meshheading:21277964-Chemistry, Pharmaceutical, pubmed-meshheading:21277964-Cholesterol, pubmed-meshheading:21277964-Cytoplasm, pubmed-meshheading:21277964-Drug Carriers, pubmed-meshheading:21277964-Electrophoresis, Polyacrylamide Gel, pubmed-meshheading:21277964-Fibroblast Growth Factor 2, pubmed-meshheading:21277964-Humans, pubmed-meshheading:21277964-Mice, pubmed-meshheading:21277964-Micelles, pubmed-meshheading:21277964-Microscopy, Atomic Force, pubmed-meshheading:21277964-Microscopy, Electron, Transmission, pubmed-meshheading:21277964-Microscopy, Fluorescence, pubmed-meshheading:21277964-Molecular Structure, pubmed-meshheading:21277964-Particle Size, pubmed-meshheading:21277964-Peptide Fragments, pubmed-meshheading:21277964-Polyethylene Glycols, pubmed-meshheading:21277964-Protein Binding, pubmed-meshheading:21277964-Receptors, Fibroblast Growth Factor, pubmed-meshheading:21277964-Solubility, pubmed-meshheading:21277964-Surface Properties, pubmed-meshheading:21277964-Surface-Active Agents
pubmed:year
2011
pubmed:articleTitle
A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells.
pubmed:affiliation
State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, People's Republic of China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't